Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics
Verve Therapeutics Inc (NASDAQ:VERV) entered into an Amended and Restated Collaboration and License Agreement with Beam Therapeutics Inc (NASDAQ:BEAM), which amended…
BMO Capital Initiates Coverage On Verve Therapeutics with Outperform Rating, Announces Price Target of $48
BMO Capital analyst Kostas Biliouris initiates coverage on Verve Therapeutics (NASDAQ:VERV) with a Outperform rating and announces Price Target of $48.
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Verve Therapeutics Reports Durable And Well-tolerated Editing Of ANGPTL3 Gene Out To More Than 20 Months In Non-human Primates For Potential Treatment Of Atherosclerotic Cardiovascular Disease
Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, reported updated preclinical data in non-human primates (NHPs)
68 Biggest Movers From Yesterday
Gainers
Sonim Technologies, Inc. (NASDAQ: SONM) shares jumped 103.3% to settle at $1.22 on Tuesday after the company announced its XP8 smartphone has integrated with the Walkie Talkie in Microsoft Teams.